Skip to main content
S. 4332 119th Congress Senate

Medication Competition Act

Official title: A bill to require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible.

Introduced: April 16, 2026 Introduced by: Margaret Wood Hassan Democratic · New Hampshire See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 16, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 16, 2026
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now April 16, 2026

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 2

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

Cite this page click to expand
APA
U.S. Congress. (2026). S. 4332: Medication Competition Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-4332/
MLA
"S. 4332: Medication Competition Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-4332/.
Bluebook (legal)
S. 4332, 119th Cong. (2026), https://openamerica.io/bill/119-S-4332/.
Markdown link
[S. 4332: Medication Competition Act](https://openamerica.io/bill/119-S-4332/)
Report a problem